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There just aren’t a lot of experts that can write the gospel of how to handle the patientwith pulmonary metastases, and that is why the article by Internullo1 in this edition of
the Journal of Thoracic Oncology is so valuable. The thoracic surgical community must
at times take stock of itself and make sure that the message for the management of these
patients, although not carved in evidence-based tablets of stone, is reasonable.
Frankly what we learn from the article are not long term results from the manage-
ment of these patients, as documented in the International Registry2 (which remains the
standard of care with regard to this topic), but that the European Society of Thoracic
Surgeons has incorporated the most important principles of management into their diverse
practices which conform to “guidelines” which have been published in the literature
before. First of all, if the primary is not controlled, it makes no sense to do a
metastasectomy. Nevertheless, there is some controversy here, especially in the case of the
synchronous presentation of metastases and primary lesion since there is a feeling among
the group that this is not a good situation as 47% felt that this is a contraindication to
metastasectomy. This is one of many situations with metastasectomy that requires
exploration of the circumstances and careful tailored management, i.e., if the patient has
a limb sarcoma and the decision is whether to perform an amputation or limb salvage in
the patient presenting with pulmonary metastases, would it not be useful to know whether
the metastases were resectable? If they were not, then every attempt would be made to
perform a local operation which would not remove the limb. The corollary is that with the
synchronous presentation, if the primary lesion can be controlled with local or systemic
therapy, then why would you not follow with a metastasectomy if the patient were deemed
to be a resection candidate after control of the primary?
How aggressive to be with this population, with regards to the extent of resection as
well as the approach to achieve that “complete resection” also remains a point of
controversy. It’s a relatively simple decision if there is only one new pulmonary nodule,
and this is usually the case with a previous carcinoma. Moreover, the reason to operate
may not just be to remove a possible metastasis but to make sure that the patient does not
have a secondary lung cancer. When there are multiple nodules, however, it is encour-
aging to see that the European community endorses resection even if they are bilateral.
Despite some surgeons who will limit the number of redo explorations to five, one gets the
feeling that an aggressive approach is used for the management of these patients, similar
to the approach used in the United States.
But . . . . what don’t we know? We don’t know whether surgery is really prolonging
the lives of these patients in the absence of a randomized trial. Will a randomized trial ever
be done to answer this question? I seriously doubt it due to the heterogeneity of
approaches, indications, and low numbers of patients to put in the trial without interna-
tional cooperation. What one should ask, however, and why thoracic surgeons are looking
over their shoulder, is whether surgery will persist as the mechanism for local control of
these lesions. With the remarkable advances in 4-D techniques for the delivery of radiation
therapy, as well as the international interest in stereotactic body radiation therapy,3 will
surgery remain the standard procedure for ablation of these lesions? Will patients prefer
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an operation, as opposed to 3 sessions of 10 to 20 minutes of
Stereotactic Body Radiation Therapy (SBRT) even if they are
strapped in a body frame? Personally, I think it is going to be
difficult for surgeons to compete with these new technologies,
even if the surgeons argue that they can do it by video-assisted
thoracoscopic surgery, with low operative mortality. The
name of the game in 2008 is minimally invasive with minimal
toxicity, and that is where novel radiation therapies as well as
percutaneous cold probes and microwaves and radiofre-
quency waves are going. Trials are already being set up for
SBRT to be used in patient with resectable lung cancer; some
institutions are already “off label” treating pulmonary metas-
tases with stereotactic techniques.4,5
This is where evidenced-based thinking must go with
metastasectomy. Before there is no standardization of SBRT
methodology for lung metastases, we need to think about single
metastasis trials comparing the new techniques to surgery . . .
whatever surgery . . . . but consistent surgery (most likely by
wedge resection). Truly such a trial will be limited by the size
and number of nodules and their location (SBRT toxicity
profiles for the lung are well described for peripheral lesions
but not for central ones), but clinicians need to know that the
new therapies are at least as effective as the standard invasive
ones when used in the proper context.
We might find out that the future of metastasectomy is
turning on the beam and turning off the lights in the operating
room, but let’s do this with some evidence behind it.
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